期刊
CYTOKINE & GROWTH FACTOR REVIEWS
卷 26, 期 6, 页码 625-635出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2015.07.016
关键词
Fibroblast growth factor 15/19; Bile acid signaling; Nuclear receptors; Liver disease; Obesity; Energy metabolism
资金
- Schweizerischer Nationalfonds SNF [310030_135548]
- Else Kroner-Fresenius-Stiftung EKFS [2014_A67]
- Deutsche Forschungsgemeinschaft [SFB 688, TP A20]
- IZKF Wurzburg [A-242]
- Faculty of Medicine of the University of Wurzburg
- Swiss National Science Foundation (SNF) [310030_135548] Funding Source: Swiss National Science Foundation (SNF)
The gut-derived hormone fibroblast growth factor 15/19 (FGF15/19) is an emerging versatile regulator of various metabolic pathways. As such, FGF15/19 has been implicated in homeostatic control of bile acid, carbohydrate and lipid metabolism in multiple target organs including the liver, adipose tissue and brain. In line with this, growing evidence suggests that dysregulation of FGF15/19 contributes to a number of metabolic and bile acid-associated disorders such as fatty liver disease, Type 2 diabetes and different gastrointestinal dysfunctions. In this review we summarize the current knowledge on the organ-specific functions of FGF15/19 and address their underlying molecular mechanisms. Moreover, recent advances in the characterization of factors that control the release of the hormone in the gut will be discussed and linked to the current view of how alterations of FGF15/19 signaling may contribute to disease development. Finally, the suitability of FGF15/19 as a potential therapeutic target will be critically reviewed. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据